Related references
Note: Only part of the references are listed.Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Francais de la Sclerose en Plaques registry
Gabrielle Simoneau et al.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)
Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry
Knut Wehrle et al.
JAMIA OPEN (2022)
A two-stage prediction model for heterogeneous effects of treatments
Konstantina Chalkou et al.
STATISTICS IN MEDICINE (2021)
Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System
Arnfin Bergmann et al.
FRONTIERS IN DIGITAL HEALTH (2021)
A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis
Fabio Pellegrini et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis
E. Stuehler et al.
BMC MEDICAL RESEARCH METHODOLOGY (2020)
Estimation and Validation of Ratio-based Conditional Average Treatment Effects Using Observational Data
Steve Yadlowsky et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2020)
Towards personalized therapy for multiple sclerosis: limitations of observational data
Ewout W. Steyerberg et al.
BRAIN (2018)
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
Stefan Braune et al.
JOURNAL OF NEUROLOGY (2018)
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Tomas Kalincik et al.
BRAIN (2017)
Effectively Selecting a Target Population for a Future Comparative Study
Lihui Zhao et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2013)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)